ArticleJournal of virology1999
Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 77 citations in OpenAlex.
- Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.Biochemical pharmacology · 2021Review
- Gene therapeutic approaches to inhibit hepatitis B virus replication.World journal of hepatology · 2015Review
- Engineered RNase P ribozymes effectively inhibit human cytomegalovirus gene expression and replication.Viruses · 2014Article
- RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1.BioMed research international · 2013Article
- Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.Journal of ophthalmology · 2011Article
- Engineered external guide sequences are highly effective in inducing RNase P for inhibition of gene expression and replication of human cytomegalovirus.Nucleic acids research · 2006Article
- Inhibition of viral replication by ribozyme: mutational analysis of the site and mechanism of antiviral activity.Journal of virology · 2005Article
- RNase P ribozyme inhibits cytomegalovirus replication by blocking the expression of viral capsid proteins.Nucleic acids research · 2004Article
- Targeted ribonuclease can inhibit replication of hepatitis B virus.World journal of gastroenterology · 2003Article
- Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus.Nucleic acids research · 2002Article
- Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro.World journal of gastroenterology · 2002Article
- Effective inhibition of herpes simplex virus 1 gene expression and growth by engineered RNase P ribozyme.Nucleic acids research · 2001Article
- Selection of targets and the most efficient hairpin ribozymes for inactivation of mRNAs using a self-cleaving RNA library.EMBO reports · 2001Article
- C-SPACE (cleavage-specific amplification of cDNA ends): a novel method of ribozyme-mediated gene identification.Nucleic acids research · 2001Article
- Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.Nucleic acids research · 2001Article
- Anti-viral activity of hairpin ribozyme directed against HBV core region in vitro.Journal of Tongji Medical University = Tong ji yi ke da xue xue bao · 2001Article
- HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.Nucleic acids research · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
A combinatorial screening method has been used to identify hairpin ribozymes that inhibit hepatitis B virus (HBV) replication in transfected human hepatocellular carcinoma (HCC) cells. A hairpin ribozyme library (5 x 10(5) variants) containing a randomized substrate-binding domain was used to identify accessible target sites within 3.3 kb of full-length in vitro-transcribed HBV pregenomic RNA. Forty potential target sites were found within the HBV pregenomic RNA, and 17 sites conserved in all four subtypes of HBV were chosen for intracellular inhibition experiments. Polymerase II and III promoter expression constructs for corresponding hairpin ribozymes were generated and cotransfected into HCC cells together with a replication-competent dimer of HBV DNA. Four ribozymes inhibited HBV replication by 80, 69, 66, and 49%, respectively, while catalytically inactive mutant forms of these ribozymes affected HBV replication by 36, 28, 0, and 0%. These findings indicate that the inhibitory effects on HBV replication were largely mediated by the catalytic activity of the ribozymes. In conclusion, we have identified catalytically active RNAs by combinatorial screening that mediate intracellular antiviral effects on HBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.